MediBuddy raises $20mn funding from India Life Sciences Fund III, others

Representational image

Health-tech company MediBuddy on Monday said it raised USD 20 million (about Rs 145 crore) earlier this month from India Life Sciences Fund III, LLC and others.

The company had announced an initial funding of USD 20 million in June last year under the series B round, a statement said.

"The additional infusion of USD 20 million led by India Life Sciences Fund III, LLC, with participation from other investors," it added.

The series B round has attracted new investments from India Life Sciences Fund III, LLC, TEAMFund LP, JAFCO Asia Fund, FinSight Ventures, ALES Global Japan and Beyond Next Ventures.

The round has also seen participation from existing investors including Bessemer Venture Partners, Milliways Ventures and Rebright Partners. The company has raised over USD 50 million so far.

Founded by Satish Kannan and Enbasekar, MediBuddy's platform has a partner network of over 90,000 doctors, 7,000 hospitals, 3,000 diagnostic centres and 2,500 pharmacies, and a 1,000-member team located across 22 Indian cities.

"We will utilize the funding in further strengthening our doctor and hospital base, patient reach, product, technology, and brand; to move a step closer to our mission of providing high-quality healthcare to a billion people," MediBuddy co-founder and CEO Satish Kannan said.

Additionally, the company has onboarded leading industry professionals over the last few months to drive critical areas, bolstering an already-strong leadership team, he added.

Last week, InnoVen Capital had announced investing Rs 25 crore in debt fund into MediBuddy. This debt fund is a part of the USD 40 million round, Kannan said.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel